by The global EYLEA drug market is witnessing significant growth driven by rising preference for anti-VEGF drug therapy in treating retinal diseases. EYLEA, which is an anti-VEGF drug, has emerged as a promising treatment option for various ocular conditions including wet age-related macular degeneration (AMD), diabetic retinopathy (DR), and macular edema following retinal vein occlusion (RVO). The drug provides effective inhibition of abnormal blood vessel growth and leakage, thereby helping restore vision and prevent further vision loss.
EYLEA, developed and marketed by Regeneron Pharmaceuticals, works by inhibiting Vascular Endothelial Growth Factor A (VEGF-A) which plays a key role in the development of neovascular retinal diseases. The drug is administered via intravitreal injections directly into the eye at regular intervals and has demonstrated long-term efficacy and safety in managing various retinal vascular diseases.
The Global EYLEA Drug Market Size is estimated to be valued at US$ 8.79 Bn in 2024 and is expected to exhibit a CAGR of 7.2% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the global EYLEA drug market are Bayer, Regeneron Pharmaceuticals, Coherus BioSciences, Inc., and Klinge Biopharma.
Rising prevalence of retinal conditions such as AMD, DR, and RVO due to aging population and increasing lifestyle-related risk factors is fueling the demand for anti-VEGF drugs globally.
Leading manufacturers are expanding their drug portfolio and presence across international markets through strategic collaborations and licensing agreements to tap growth opportunities.
Market Key Trends
One of the key trends witnessed in the global EYLEA drug market is the increasing adoption of anti-VEGF drugs over laser photocoagulation and photodynamic therapy. Anti-VEGF drugs offer better visual outcomes along with fewer side effects and re-treatmentsessions. Continuous research efforts are underway to develop biosimilars and extended efficacy versions of EYLEA to increase treatment compliance and outcomes through less frequent administrations. Manufacturers are also exploring opportunities in emerging countries in Asia Pacific and Latin America with growing incidence of retinal disorders.
Porter’s Analysis
Threat Of New Entrants: The biopharmaceutical industry requires high capital investments and strict regulations which limits the threat of new entrance.
Bargaining Power Of Buyers: Large pharmaceutical companies have significant bargaining power over suppliers and manufacturers due to their size and purchasing power.
Bargaining Power Of Suppliers: Suppliers of raw materials and manufacturing equipment have lower bargaining power due to presence of many suppliers.
Threat Of New Substitutes: Limited number of substitute products exist for Eylea due to its strong clinical profile and patented nature.
Competitive Rivalry: Intense competition exists between major pharmaceutical companies to gain market share and maximize profits.
Geographical Regions
The United States accounts for over half of the global Eylea market value due to the country’s large healthcare expenditure and high adoption rate of innovative therapies.
Asia Pacific region is expected to be the fastest growing market during the forecast period driven by rising healthcare spending, growing cases of age-related macular degeneration and diabetic retinopathy in countries like China and India.
What Are The Key Data Covered In This Global EYLEA Drug Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Global EYLEA Drug Market’s growth between 2024 and 2031.
:- Accurate calculation of the size of the Global EYLEA Drug Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Global EYLEA Drug Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Global EYLEA Drug Market vendors
FAQ’S
Q.1 What are the main factors influencing the Global EYLEA Drug market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Global EYLEA Drug Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Global EYLEA Drug market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
